24O - Clinical utility of a plasma-based microRNA signature classifier within computed tomography lung cancer screening

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 3 - Screening, staging and epidemiology
Topics Cancer Aetiology, Epidemiology, Prevention
Lung and other Thoracic Tumours
Translational Research
Presenter Ugo Pastorino
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors U. Pastorino1, M. Boeri2, G. Sozzi2
  • 1Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT



Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung-cancer mortality in high risk subjects. However, high false positive rates, costs and potential harms highlight the need for complementary biomarkers. MicroRNAs (miRNAs) are tissue and disease specific molecules, actively released by cells in the circulatory system, which are associated with protein complexes and/or packaged in exosomes and microvesicles. Circulating miRNAs are rather stable and easily detectable in body fluids suggesting the possibility of using miRNAs as a new promising class of biomarkers. We previously reported that miRNA profiling in plasma samples of disease-free smokers enrolled in two independent spiral-CT screening trials, resulted in the generation of miRNA signatures with strong predictive, diagnostic, and prognostic potential (Boeri et al. PNAS 2011).